Watch
4SC Awarded First Place and International Platinum Award for its 2009 Annual Report in the Biotech Category
(PresseBox) (Planegg-Martinsried, )
4SC AG (Frankfurt, Prime Standard: VSC) a drug discovery and development company focused on autoimmune and cancer indications, won first place and the platinum award, the highest level award, from the League of American Communications Professionals (LACP) for its annual report 2009 in the biotech category.
The jury of the LACP, based in San Diego, USA, appraised over 4,000 international annual reports this year from over 29 countries. In addition to evaluating the transparency and information content of various sections, the creativity and design were also assessed. 4SC's annual report reached 75th place overall amongst the 4,000 submitted, international annual reports.
Ulrich Dauer, Chief Development Officer of 4SC commented, "We are very happy that our annual report 2009 has received international recognition. The positive response shows that we are on the right track with our approach of providing transparent and clear facts to our shareholders, but also by highlighting the people who stand behind 4SC and enable the company's progress."
The jury of the LACP, based in San Diego, USA, appraised over 4,000 international annual reports this year from over 29 countries. In addition to evaluating the transparency and information content of various sections, the creativity and design were also assessed. 4SC's annual report reached 75th place overall amongst the 4,000 submitted, international annual reports.
Ulrich Dauer, Chief Development Officer of 4SC commented, "We are very happy that our annual report 2009 has received international recognition. The positive response shows that we are on the right track with our approach of providing transparent and clear facts to our shareholders, but also by highlighting the people who stand behind 4SC and enable the company's progress."
4SC AG
4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in a Phase IIb study in rheumatoid arthritis and a Phase IIa exploratory study in inflammatory bowel disease. The company's lead oncology compound, resminostat (4SC-201), a pan histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma and Hodgkin's lymphoma. Two further oncology compounds, 4SC-203 and 4SC-205 are in Phase I studies. 4SC develops drug candidates until proofofconcept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
For further information please visit www.4sc.com.
